STAT+: Underpinning Sinema’s outspoken opposition to major drug pricing reforms: her close ties to Arizona biotechs
Phoenix, Ariz. is no Kendall Square. Its biotech companies, ventures like OncoMyx Therapeutics and VisionGate, haven’t generated one-tenth the buzz of companies like Moderna or CRISPR Therapeutics.
But if congressional Democrats’ drug pricing reforms fail, the tiny biotechs that pepper the Grand Canyon State deserve an outsized bit of the credit.
